J.B. Chemicals & Pharmaceuticals Limited has fixed May 29, 2026, as the record date to determine shareholder eligibility for the final dividend for the financial year 2025-26. The announcement was made in compliance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The record date is essential for identifying the beneficial owners and shareholders entitled to receive the declared dividend. Only those shareholders listed in the company's records on this specific date will qualify for the payout.

Record Date Details

The following table outlines the key specifics regarding the corporate announcement:

Shareholders holding equity shares are advised to ensure their holdings are updated in the depository records to avail the dividend benefit. The company has requested the stock exchange to take this intimation on record.

J. B. Chemicals & Pharmaceuticals Limited reported its consolidated audited financial results for Q4 FY26 and the full year FY26. The Board of Directors approved the results at their meeting held on May 11, 2026. The company subsequently hosted a Q4 FY26 Earnings Conference Call on May 12, 2026, with management providing detailed commentary on financial performance, integration progress with parent entity Torrent Pharma, and the outlook across business segments.

Financial Performance

The company recorded consolidated revenue of INR 904 crores in Q4 FY26, a decline of 5% year-on-year from INR 949 crores in Q4 FY25. Reported profit after tax (PAT) fell 30% to INR 101 crores from INR 146 crores in the corresponding quarter. Management noted that one-off charges during the quarter, including non-cash ESOP charges, amounted to INR 40 crores. Adjusted for these one-offs, PAT stood at INR 150 crores, and EBITDA was flat at INR 241 crores. Gross margin improved to approximately 70% from 66% in Q4 FY25, while adjusted EBITDA margin improved by approximately 2% to 27% from 25% in the corresponding quarter. For the full year FY26, revenue grew 6% to INR 4,148 crores from INR 3,918 crores, and PAT rose 8% to INR 709 crores from INR 659 crores. The Board also recommended a final dividend of INR 9.30 per equity share of INR 1 each for FY26, subject to shareholder approval. Net cash as of FY26 stood at approximately INR 1,200 crores.

*Before one-offs

Segment Performance

Management provided a detailed breakdown of performance across the India, International Formulations, and CDMO segments. The India business grew 2% year-on-year in Q4 FY26 to INR 526 crores, with the sequential slowdown attributed primarily to the discontinuation of the trade generics business. Excluding trade generics, the branded India business grew 8% in the quarter. For the full year FY26, the India business grew 9% to INR 2,461 crores, with the branded business growing 11%. As per IQVIA MAT March 2026 data, the India business grew at 11% versus IPM growth of 10%, and the chronic business grew at 19% versus industry growth of 14%. The International Formulations business reported a de-growth of 9% in Q4 FY26 to INR 259 crores, impacted by container shipment constraints to the Middle East and parts of Asia, as well as alignment of sales closing and credit policies with Torrent. For the full year FY26, international formulations revenue grew 2% to INR 1,154 crores. The CDMO business revenues declined 22% in Q4 FY26 due to a high base in the corresponding quarter of the previous year, while for the full year FY26, CDMO revenues were flat at INR 445 crores.

Torrent Integration and Operational Reset

Q4 FY26 marked the first quarter for JB Pharma following the change in control, with Torrent Pharma having acquired a controlling stake on January 21, 2026. Management described Q4 as a period of operational reset, which temporarily impacted performance. Key integration steps undertaken during the quarter included optimisation of the distribution network, discontinuation of the low-margin trade generics portfolio in India, and alignment of trade and sales closing practices—including credit period, field incentives, and cut-off policies—with the parent entity. The trade generics business contributed approximately 7% to 8% of the overall India top line until Q3, and management indicated this segment would not be a focus going forward. The company's field force in India currently stands at approximately 2,500 medical representatives, with no changes made to the field force during the quarter. On the merger process, the company has received requisite shareholder approvals for the merger of JB Pharma with Torrent, with a court hearing date scheduled in the second week of June. Management indicated the merger is expected to become effective within one to two months.

Synergy Strategy and Outlook

Management outlined the key synergy levers expected from the Torrent-JB integration, focusing on the India branded business as the primary growth driver. Revenue synergies are expected to be driven by enhanced coverage of JB's chronic and cardiac brands, leveraging Torrent's distribution reach, with early positive signs already observed. Cost synergies are expected from procurement optimisation, distribution network rationalisation (already implemented and expected to reflect in margins from April), and reduction of overlapping corporate overhead functions. On the CDMO business, management highlighted that growth drivers include expanding the geographic footprint within existing top-tier customers such as Innova, Kenvue, P&G, and Reckitt, increasing wallet share with existing customers, and executing on contracts already signed. The key challenge identified was accelerating product development and execution timelines, given a lean development organisation. Management indicated that normalization of the India branded business to double-digit or low-teens growth could take a couple of quarters, while international business single-digit growth is expected to resume potentially from Q1, with more certainty from Q2 onwards.